In a pivotal move that may echo across international borders, the United States Drug Enforcement Administration (DEA) is considering the rescheduling of cannabis, a decision that could significantly influence Australian policies and the lives of medicinal cannabis users, including veterans.
The United States Department of Health and Human Services recognises cannabis as a medication that is used to treat a range of conditions including post traumatic stress disorder (PTSD). As such in August 2023 it recommended to the DEA that cannabis be rescheduled to a schedule 3 drug.
The DEA's reconsideration could shift cannabis to a lesser schedule, acknowledging its medical benefits and potentially easing research restrictions. This shift is keenly observed by Australian health policy experts and medicinal cannabis advocates, who anticipate similar policy reconsiderations on local shores.
Australia has seen a growing acceptance of medicinal cannabis, particularly among its veteran community, who use it primarily for chronic pain management and post-traumatic stress disorder (PTSD). The majority of Australian veterans have reportedly reduced their pharmaceutical medication intake by up to 90%, with some ceasing conventional medications entirely, thanks to prescribed cannabis treatments.
The potential U.S. policy change could streamline access to medicinal cannabis, reduce costs, and expand research opportunities, making it a more viable alternative to traditional pharmaceuticals in Australia. Advocates argue that this could enhance the quality of life for patients who rely on cannabis for therapeutic purposes.
Simultaneously, the Royal Commission into Defence and Veteran Suicide, currently underway, is investigating multiple factors contributing to veteran suicides, including the role of polypharmacy — the simultaneous use of multiple drugs by a single patient, often for different conditions. Submissions have highlighted concerns about the correlation between polypharmacy and increased suicide risks among veterans.
The Commission's findings could lead to significant changes in how medicinal treatments, including cannabis, are integrated into healthcare regimens for veterans. Advocates are calling for a cautious but open-minded approach to incorporating cannabis treatment, hoping for a reduction in polypharmacy and its associated risks.
The Australian government remains cautious, balancing between international drug policy shifts and local public health concerns. However, as the global perspective on cannabis shifts towards a more medical-focused view, Australian policies may align more closely with those of the United States, potentially leading to profound impacts on the use of medicinal cannabis and the overall well-being of its users, particularly those who have served in the military.
As discussions unfold both in the U.S. and Australia, stakeholders from healthcare professionals to veteran support groups remain vigilant, understanding that the DEA's decision could herald a new era in medicinal treatment and veteran care.